Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Intravenous Physical Compatibility of Heparin Sodium and Furosemide

Author(s):  Maktabi Briana, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D

Issue:  Nov/Dec 2022 - Volume 26, Number 6
View All Articles in Issue

Page(s):  522-526

Intravenous Physical Compatibility of Heparin Sodium and Furosemide Page 1
Intravenous Physical Compatibility of Heparin Sodium and Furosemide Page 2
Intravenous Physical Compatibility of Heparin Sodium and Furosemide Page 3
Intravenous Physical Compatibility of Heparin Sodium and Furosemide Page 4
Intravenous Physical Compatibility of Heparin Sodium and Furosemide Page 5

Download in electronic PDF format for $65

Abstract:  Continuous infusions of heparin and furosemide are often required for hospitalized patients to treat cardiac-related disease states. Concomitant infusion of heparin and furosemide through the same intravenous line minimizes the need for multiple intravenous sites. For concomitant infusions to be administered, knowledge of the physical compatibility for intravenous medications is imperative for patient safety and administering medications to maximize their effectiveness. Currently, heparin and furosemide are listed as Y-site compatible, but precipitation was reported at a large academic medical center, which questions this compatibility. This study investigated the in vitro physical compatibility of heparin sodium premix 25,000 units/250 mL in dextrose 5% water from two different manufacturers with furosemide 40 mg/4 mL at concentrations of 4:1 for heparin sodium and furosemide. The admixtures were prepared in triplicate using aseptic technique, stored at 19°C to 24°C and examined for visual precipitation, turbidity, and pH change at baseline, 1, 5, 8, 24, and 48 hours. Heparin sodium, B. Braun Medical Inc. or Hospira, Inc. solutions, and furosemide admixtures revealed changes over 48 hours. Changes in visual appearance, absorbance, and pH were observed at hour 5 compared to baseline for the B. Braun Medical Inc. admixture. The Hospira, Inc. admixture revealed visual changes by hour 48, but demonstrative changes in absorbance and pH did not occur. Our observations found demonstrative changes in physical compatibility in the admixtures of heparin sodium and furosemide at a ratio of 4:1. The findings suggest that a combination of the solutions in this study be avoided until further research is completed.    

Related Keywords: Briana Maktabi, MSPS, Mitchell S. Howard, PharmD, MBA, BCACP, Gabriella Baki, PhD, Mariann D. Churchwell, PharmD, FCCP, BCPS, heparin sodium, continuous intravenous infusion, thromboembolism, furosemide, loop diuretic, drug admixture, Y-site compatibility, physical stability, chemical stability, physical compatibility, drug trapping, precipitates, excipients, turbidity

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, HEMOSTASIS, BLEEDING, ANTICOAGULATION

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana
, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
Nov/Dec 2022
Pg. 522-526

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Lu Juan
, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
Jan/Feb 2021
Pg. 52-61

Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G
, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
May/Jun 2020
Pg. 238-241

Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration
Mody Vicky
, Shah Samit, Patel Jaymin, Thomas Michael C
May/Jun 2016
Pg. 236-238

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Stability of Furosemide 5 mg/mL in Polypropylene Syringes
van der Schaar JAJ
, Grouls R, Franssen EJF, Crul M
Sep/Oct 2019
Pg. 414-417

Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration
Chan Pak
, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A
May/Jun 2008
Pg. 276-278

Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig
, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Mar/Apr 2008
Pg. 156-160

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions